Document is current

Article History

Received: 12 November 2024

Accepted: 6 April 2025

First Online: 23 April 2025

Declarations

:

: M.G. has received honoraria for speaker fees and/or travel grants for scientific meetings from AAA, AstraZeneca, Boehringer-Ingelheim, Bruno Farm., Eli-Lilly, IBSA, Lifescan, Mundipharma, Novo Nordisk and Sanofi, and served on scientific advisory panels for Boehringer-Ingelheim, Merck Sharp & Dohme and Novo Nordisk. A.L. declares grants for consultancies/advisory boards from GSK, and speaking fees from Astrazeneca, GSK, Novartis, Pfizer. V.R. has received a travel grant from Androlabs. A.N. has served as a speaker for AstraZeneca, Lilly Boehringher, Novo Nordisk, and Sanofi Aventis. F.G. has served as an advisor for AstraZeneca, Eli Lilly and Novo Nordisk; has served as a research investigator for Eli Lilly and Roche Diabetes Care; has served as a speaker for AstraZeneca and Eli Lilly; has served as a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care and Sanofi; has received grants from Eli Lilly, Lifescan and Roche Diabetes Care; leadership in scientific society: Senior Vice President of EASD. S.F. serves on the scientific advisory board of, has a consulting relationship with and reports receiving support for travel expenses from Novartis, Teva, Roche, BMS, Lilly and Ipsen. R.C. has received grants and consultancy or lecture fees from Abbott, AstraZeneca, Bayer, Boehringer, Lilly, MSD, Menarini Diagnostics, Mundipharma, Novo Nordisk, Roche Diabetes Care, and Sanofi. G.A. has received grants from Eli Lilly and Novo Nordisk. N.S. received fees for consulting from Roche, Lilly, Servier. All other authors have declared no conflicts of interest.

: Not applicable.